Issue link: https://www.e-digitaleditions.com/i/1248960
Pharmaceutical Technology BIOLOGICS AND STERILE DRUG MANUFACTURING 2020 23 and needles with reduced amounts of silicone, adds Sacha. "Both solutions can be helpful for reducing interactions with the molecule and silicone," he says. "In addition, using less silicone on needles can pre- vent, or at least reduce, the amount of silicone that is deposited in the injection site, which is particularly useful in intraocular injection." Discussing drug delivery devices further, I'ons reveals that there are several trends taking place and emerging within the industry. "Many compa- nies are working on designs for connected devices, which allow the transmission of key usage data from the device to the pharma company and third par- ties, such as payors," he says. "In addition, the use of devices connected to apps creates an opportunity for pharma to provide the patient with education, train- ing, and support around their medication and disease management. It is hoped that provision of this type of information will aid compliance and ultimately may positively impact patient outcomes." Furthermore, I'ons points out that there is an in- creasing focus on sustainability. "This focus is also resulting in pharma companies examining the num- ber of disposable devices they market and therefore looking at alternatives such as reusable devices to help reduce waste," he summarizes. References 1. Global Market Insights, "Prefilled Syringes Market Size by Type (Glass, Plastic), by Design (Single-Chamber, Dual-Chamber), by Applications (Diabetes, Rheumatoid Arthritis, Anaphylaxis, An- tithrombotic/Thrombolytic Therapy), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019–2025," gminsights.com, July 2019. 2. M.F. Tatelbaum, Pain Physician, 4 (2) 193–195 (2001). 3. European Commission, "Council Directive 2010/32/EU of 10 May 2010 Implementing the Framework Agreement on Prevention from Sharp Injuries in the Hospital and Healthcare Sector Concluded by HOSPEEM and EPSU" (Brussels, July 17, 2009). PT I N T E R N A T I O N A L C E N T R E F O R D I F F R A C T I O N D A T A ICDD databases are the only crystallographic databases in the world with quality marks and quality review processes that are ISO certified. PDF-4/Organics Diffraction Data You Can Trust Solve Difficult Problems, Get Better Results 538,500 + Entries 118,000 + Atomic coordinates Targeted Collection for Commercial & Regulatory Fields Combines Crystalline, Semicrystalline, and Amorphous Solid State Materials SIeve+, Search Indexing Software, Included as an Added Value Molecular Graphics and Digitized Patterns 2020 Powder Diffraction File ™ Standardized Data More Coverage All Data Sets Evaluated For Quality Reviewed, Edited and Corrected Prior To Publication Targeted For Material Identification and Characterization ISO 9001:2015 ISO 9001:2015 BY DEKRA CERT. NO. 110409.01 BY DEKRA CERT. NO. 110409.01 www.icdd.com | marketing@icdd.com ICDD, the ICDD logo, PDF and JADE are registered in the U.S. Patent and Trademark Office. Powder Diffraction File, Materials Data, Materials Data-JADE logo, and Denver X-ray Conference logo are trademarks of the JCPDS-International Centre for Diffraction Data. ©2020 JCPDS-International Centre for Diffraction Data. – 4/20/20 Room temperature crystal structure publication for Atazanavir, a potential drug for treating COVID-19, is available from International Centre for Diffraction Data, ICDD ® Read the Powder Diffraction Journal paper for Free Now via Cambridge CoreShare: https://doi.org/10.1017/S0885715620000135